Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis
Rebound-associated vertebral fractures after discontinuation of denosumab for the treatment of maxillitis
复制标题
停止使用狄诺塞麦治疗上颌炎后出现反弹相关的椎骨骨折
DOI：
10.1007/s00198-017-4334-3
复制
发表时间：
2018
影响因子：
4
通讯作者：
A. Sudo
中科院分区：
文献类型：
--
作者：
R. Niimi;T. Kono;A. Nishihara;M. Hasegawa;A. Sudo
我们报告了1例69岁女性患者，因牙科治疗而停用地舒单抗，随后在末次注射后10个月发生反弹相关椎体骨折。该病例引起了关于停用地舒单抗进行牙科治疗的警报。据我们所知，Denosumab是一种皮下注射给药的人单克隆抗体，是唯一一种经过充分研究的核因子κ B配体受体激活剂抑制剂。停用地舒单抗导致骨转换反弹和骨密度快速丢失。几项研究报告了地舒单抗停药后反弹相关的椎骨骨折。我们报告了一个新的情况下，反弹相关的椎骨骨折后，停用地舒单抗。1例69岁女性患者，3年后因上颌骨炎退出地舒单抗治疗，因重度腰痛到我院就诊，无任何创伤史。距离上次注射已经过去了十个月。磁共振成像显示5例急性椎骨骨折，似乎是因牙科治疗而停用地舒单抗引起的反弹相关椎骨骨折。该病例明确证明了停用地舒单抗进行牙科治疗的风险。
We reported a 69-year-old female who discontinued denosumab due to dental treatment and subsequently suffered rebound-associated vertebral fractures 10 months after the last injection. This case raised an alarm regarding the discontinuation of denosumab for dental treatment. Denosumab, a human monoclonal antibody administered by subcutaneous injection, to the best of our knowledge, is the only fully investigated inhibitor of receptor activator of nuclear factor kappa B ligand. Discontinuation of denosumab leads to bone turnover rebound and rapid bone mineral density loss. Several studies have reported rebound-associated vertebral fractures after discontinuation of denosumab. We report on a new case of rebound-associated vertebral fractures after discontinuation of denosumab. A 69-year-old female, who withdrew from denosumab treatment after 3 years due to maxillitis, presented to our hospital with severe low back pain without any history of trauma. Ten months had passed since the last injection. Magnetic resonance imaging showed five acute vertebral fractures, which appeared to be rebound-associated vertebral fractures caused by discontinuation of denosumab due to dental treatment. This case clearly demonstrates the risk of discontinuation of denosumab for dental treatment.